HOME >> MEDICINE >> NEWS
First large-scale clinical study establishes the efficacy of the new oral anticoagulant H 376/95

at high risk of venous thrombosis (formation of a blood clot in a vein) which may result in pulmonary embolism leading to death. A common approach to prevention of venous thromboembolism is the use of anticoagulant prophylaxis e.g. injectable low molecular weight heparin or oral warfarin. Warfarin requires careful and regular coagulation monitoring i.e. taking blood samples. Warfarin has limitations because of a slow onset of effect over several days. Also, bleeding complications and drug interactions are common. There is, therefore, a need for an effective and well-tolerated oral alternative to warfarin. The data from the METHRO II study indicate that H 376/95 shows considerable promise as a replacement for low molecular weight heparin and warfarin in the prophylaxis of venous thromboembolism in orthopaedic surgery."

The METHRO II study was a double-blind, dose-finding study and a comparator agent was used. The primary purpose of the study was to determine the dose-response relationship with regard to efficacy for the oral direct thrombin inhibitor, H 376/95, preceded by subcutaneous administration of melagatran. The METHRO II study was also designed to compare the efficacy of the H 376/95 regimen with conventional prophylaxis using the injectable low molecular weight heparin agent, dalteparin.

Patients were randomised to one of four melagatran/H 376/95 regimens or dalteparin for 8-11 days. The regimens were: 1mg, 1.5mg, 2.25mg or 3mg melagatran subcutaneously twice daily followed by 8mg, 12mg, 18mg or 24mg oral H 376/95 twice daily respectively or dalteparin 5000 IU once daily subcutaneously. A diagnostic procedure, phlebography, was carried out on the final day of treatment. Patient follow-up was 4-6 weeks post-operatively. Two-thirds of the patients underwent hip replacement and one-third knee replacement surgery. The age range was 18-85 years.

There was a clear relationship between the dose regimen of H 376/95 and the occurrence of
'"/>

Contact: Jonathan Wilson/Rebecca Hunt
jonathan.wilson@ketchumcomms.co.uk
44-207-465-7698
Ketchum
4-May-2000


Page: 1 2 3

Related medicine news :

1. First head-to-head study to compare lidoderm patch and Celebrex in treating pain
2. First UK cases of previously rare disease reported in gay men
3. First mouse model for multiple system atrophy points to new treatment targets for brain diseases
4. Mayo Clinic researchers create obedient virus; First step to use measles virus against cancer
5. First US kidney cancer vaccine trial underway at Columbia
6. First new treatment for alcoholism in ten years, now available Campral(R) (acamprosate calcium)
7. First blood test to diagnose paralyzing, blinding disease
8. First US SARS vaccine trial opens at NIH
9. First-ever safety study of medical cannabis use in Canada launched
10. First solid evidence that the study of music promotes intellectual development
11. First medical test on CD gets good results

Post Your Comments:
(Date:5/22/2015)... CA (PRWEB) May 22, 2015 ... Sunset Plaza Dental announces that they are now ... restorative and other dental treatments. At consultations, patients ... them. Questions regarding what certain treatments can achieve ... be covered during this initial appointment. If treatments ...
(Date:5/22/2015)... Boca Raton, FL (PRWEB) May 22, 2015 ... organization which provides vascular, electrocardiogram (EKG), echocardiogram and ... of David Sempier, a highly respected All American National ... a multi-sport athlete, I find the high level of ... to both the athlete and their athletic trainers, this ...
(Date:5/22/2015)... 2015 In April 2006, Veatch Consulting ... 9 years they have concentrated their focus to working ... Canada. Because of this growth and their goals to ... in Denver, Colorado, Cleveland, Ohio, Houston, Texas and now ... new dental offices, dental start ups, orthodontic practices, pediatric ...
(Date:5/22/2015)... In efforts to offer full and ... particular muscles stretches has been a large focus over ... now complete, Chunk Fitness envisions a mid-June launch of ... and released at a later point in time. The ... http://www.chunkfitness.com/stretches . , About the Company: Chunk Fitness was ...
(Date:5/21/2015)... York (PRWEB) May 21, 2015 World ... patented products, launches the Troll Motor Guide, a boat ... of boating. , "The recreational boating industry has reached ... Cooper, CEO and Creative Director of World Patent ... record numbers and predicts continued steady growth of seven ...
Breaking Medicine News(10 mins):Health News:West Hollywood Dental Office, Sunset Plaza Dental is Now Offering Complimentary Consultations 2Health News:Wimbledon Athletics Recruits Team USA Athlete 2Health News:Wimbledon Athletics Recruits Team USA Athlete 3Health News:Great Ways To Celebrate On Memorial Day Weekend- Starting With World Patent Marketing's New Boat Patent 2Health News:Great Ways To Celebrate On Memorial Day Weekend- Starting With World Patent Marketing's New Boat Patent 3
(Date:5/21/2015)... May 21, 2015 ... announced the addition of the "Arthroscopy ... offering. ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,The purpose ... size the world market for Arthroscopy Devices. ... trends impacting the market for these products. ...
(Date:5/21/2015)... NEW YORK , 21. Mai ... (NASDAQ: DPRX ), ein Unternehmen ... sich auf die Entwicklung und Vermarktung ... Forschungszusammenarbeit konzentriert, kündigte heute eine wissenschaftliche ... der Phase-III-Zulassungsstudie des Unternehmens vorstellt, OneStep-1 ...
(Date:5/21/2015)... , May 21, 2015 Research and Markets ... addition of the "Global Next Generation Sequencing ... The global next generation sequencing market to ... period 2014-2019 This report covers the ... global next generation sequencing market for the period ...
Breaking Medicine Technology:Analysing Arthroscopy Devices Markets Worldwide 2014-2020 2Analysing Arthroscopy Devices Markets Worldwide 2014-2020 3Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 2Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 3Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 4Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 5Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 6Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 7Global Next Generation Sequencing Market 2015-2019 2
Cached News: